insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.

2/5 보강
Leukemia research 📖 저널 OA 12% 2023: 0/1 OA 2025: 0/6 OA 2026: 6/43 OA 2023~2026 2026 Vol.163() p. 108187 Acute Myeloid Leukemia Research
TL;DR This study evaluated the clinical efficacy of venetoclax and azacitidine versus CAG for newly diagnosed adult acute myeloid leukemia (AML) unfit patients and showed a preference for VEN+AZA regarding OS, and patients with SRSF2 mutation favored CAG in OS.
Retraction 확인
출처
PubMed DOI OpenAlex Semantic 마지막 보강 2026-04-30

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
248 patients received VEN+AZA and 104 patients received CAG.
I · Intervention 중재 / 시술
VEN+AZA and 104 patients received CAG
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
31.7 % (P = 0.20). Patients with age ≥ 60 y (EFS, P = 0.032), ECOG≥ 2 (EFS, P = 0.047), secondary AML (OS, P = 0.015; EFS, P = 0.039), ELN intermediate-adverse karyotype (OS, P = 0.034; EFS, P = 0.044), RUNX1 mutation (OS, P = 0.003; EFS, P = 0.003) and IDH1/2 mutation (EFS, P = 0.039) showed a preference for VEN+AZA regarding OS, and patients with SRSF2 mutation favored CAG in OS (P = 0.031).
OpenAlex 토픽 · Acute Myeloid Leukemia Research Hematopoietic Stem Cell Transplantation Neutropenia and Cancer Infections

Chang G, Gao H, Wei Y, Fu Q, Jiang Q, Jiang H

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

This study evaluated the clinical efficacy of venetoclax and azacitidine versus CAG for newly diagnosed adult acute myeloid leukemia (AML) unfit patients and showed a preference for VEN+AZA regarding

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P = 0.04
  • OR 1.085

이 논문을 인용하기

↓ .bib ↓ .ris
APA Guanghui Chang, Haitao Gao, et al. (2026). Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.. Leukemia research, 163, 108187. https://doi.org/10.1016/j.leukres.2026.108187
MLA Guanghui Chang, et al.. "Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.." Leukemia research, vol. 163, 2026, pp. 108187.
PMID 41687264 ↗
DOI 10.1016/j.leukres.2026.108187

Abstract

This study evaluated the clinical efficacy of venetoclax and azacitidine (VEN+AZA) versus CAG (cytarabine, aclarubicin, and granulocyte colony-stimulating factor) for newly diagnosed adult acute myeloid leukemia (AML) unfit patients. There were 248 patients received VEN+AZA and 104 patients received CAG. A PSM (Propensity Score-Matching) was conducted using the nearest neighbor method in a 1:2 ratio to minimize bias. As a result, 170 patients in the VEN+AZA cohort were matched with 85 patients in the CAG cohort. In propensity-matched group, VEN+AZA had higher CRc rate than the CAG (all cohort, 67.9 % vs 55.5 %, P = 0.04), especially for age ≥ 60 y (OR=1.085, P = 0.04), secondary AML(OR=1.802, P = 0.028), ELN intermediate-adverse karyotype(OR=1.33, P = 0.045), DNMT3A mutation (OR=1.32, P = 0.047) and IDH1/2 mutation (OR=1.952, P = 0.049), but patients with RUNX1::RUNX1T1 (OR=0.25, P = 0.044) favored CAG in CRc rate. The 3-year OS and EFS for VEN+AZA group and CAG group were 49.8 % VS. 49.8 % (P = 0.81) and 34.3 % VS. 31.7 % (P = 0.20). Patients with age ≥ 60 y (EFS, P = 0.032), ECOG≥ 2 (EFS, P = 0.047), secondary AML (OS, P = 0.015; EFS, P = 0.039), ELN intermediate-adverse karyotype (OS, P = 0.034; EFS, P = 0.044), RUNX1 mutation (OS, P = 0.003; EFS, P = 0.003) and IDH1/2 mutation (EFS, P = 0.039) showed a preference for VEN+AZA regarding OS, and patients with SRSF2 mutation favored CAG in OS (P = 0.031).

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 3개

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반